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a  b  s  t  r  a  c  t
Glioblastoma  multiforme  (GBM)  is considered  the most  lethal  intracranial  tumor  and  the  median  survival
time  is  approximately  14 months.  Although  some  glioma  cells  present  radioresistance,  radiotherapy  has
been the mainstay  of therapy  for  patients  with malignant  glioma.  The  activation  of  P2X7  receptor  (P2X7R)
is responsible  for ATP-induced  death  in  various  cell  types.  In this  study,  we analyzed  the  importance  of
ATP-P2X7R  pathway  in the radiotherapy  response  P2X7R  silenced  cell  lines,  in  vivo and human  tumor
samples.  Both  glioma  cell lines  used  in  this  study  present  a  functional  P2X7R  and  the  P2X7R  silencing
reduced  P2X7R  pore  activity  by ethidium  bromide  uptake.  Gamma  radiation  (2 Gy) treatment  reduced
cell  number  in  a P2X7R-dependent  way,  since  both  P2X7R  antagonist  and  P2X7R  silencing  blocked  the
cell  cytotoxicity  caused  by  irradiation  after  24 h. The  activation  of  P2X7R  is  time-dependent,  as  EtBr
uptake  signiﬁcantly  increased  after 24  h  of  irradiation.  The radiotherapy  plus  ATP  incubation  signiﬁcantly
increased  annexin  V  incorporation,  compared  with  radiotherapy  alone,  suggesting  that ATP acts  synergis-
tically  with  radiotherapy.  Of note,  GL261  P2X7R  silenced-bearing  mice  failed  in  respond  to  radiotherapy
(8  Gy)  and  GL261  WT-bearing  mice,  that  constitutively  express  P2X7R,  presented  a  signiﬁcant  reduction
in  tumor  volume  after  radiotherapy,  showing  in  vivo  that  functional  P2X7R  expression  is  essential  for
an efﬁcient  radiotherapy  response  in gliomas.  We  also  showed  that  a  high  P2X7R  expression  is a  good
prognostic  factor  for glioma  radiosensitivity  and  survival  probability  in  humans.  Our data  revealed  the
relevance  of P2X7R  expression  in glioma  cells  to a successful  radiotherapy  response,  and  shed  new  light
on this  receptor  as  a useful  predictor  of  the  sensitivity  of  cancer  patients  to  radiotherapy  and  median
survival.
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. Introduction
Glioblastoma multiforme (GBM) is a malignant astrocytic
lioma (grade IV), considered the most common and lethal intracra-
ial tumor (Furnari et al., 2007). It accounts for ∼50% of cases
f primary brain tumor (Wang et al., 2012). Among the deﬁning
haracteristics of GBM are the high levels of proliferative and inva-
ive cells, as well as, a wide resistance to treatment (Chandana
t al., 2008; Cote et al., 2012). Patients with this tumor have a
oor prognosis (Fisher et al., 2007), with a median survival time
f approximately 14 months (Yang et al., 2010). The treatment of
alignant gliomas remained virtually unchanged during the last
ears (Mathieu and Fortin, 2006; Nieder et al., 2009). Although
ome glioma cells present radioresistance, radiotherapy has been
he mainstay of therapy for patients with malignant gliomas
Ohshima et al., 2010; Van Meir et al., 2010; Yang et al., 2010).
hus, the identiﬁcation of mechanisms underlying the radioresis-
ance of gliomas is essential for the development of new therapies.
ur group has shown previous in vitro evidence on the possible
nvolvement of P2X7 purinergic receptor on the radiosensitivity of
lioma cells (Gehring et al., 2012).
The purinergic system has been implicated in the pathogene-
is of several cancers (Burnstock and Di Virgilio, 2013; Morrone
t al., 2003; White et al., 2005). The purinergic signaling consists
f nucleotides and nucleosides, as adenosine triphosphate (ATP),
urinergic receptors and ectoenzymes, that hydrolyze nucleotides
e.g. ATP to adenosine) (Burnstock and Di Virgilio, 2013). Within the
umor, ATP can be released to the extracellular space from areas of
ecrosis, hemorrhage, excitotoxic, immunogenic cell death and/or
rom injury caused by the surgical tumor resection (Ma  et al., 2013b;
orrone et al., 2006). The P2X7R is a cation channel and when acti-
ated by ATP in high concentration or for a long period to ATP, can
e converted to a large nonselective transmembrane pore, which
ltimately causes cell death in the manner of apoptosis (White and
urnstock, 2006).
There is an apparent contradiction regarding the P2X7R onco-
enic or anti-tumor role. Some studies show that P2X7R exhibits
igniﬁcant growth-promoting effects in vivo inducing a more devel-
ped vascular network and elevated amounts of VEGF (Adinolﬁ
t al., 2012) and promoting cell invasion and migration (Qiu et al.,
014; Xia et al., 2015 {Qiu, 2014 #7180}). However, the exact
olecular basis of P2X7-mediated growth-promoting activity is
oorly known, but mitochondria appear to play a central role (Di
irgilio et al., 2009). On the other hand, P2X7R suppression induced
lioma growth (Fang et al., 2013) and functional P2X7R activa-
ion by ATP resulted in rapid cytotoxic effects that affects cell
rowth/survival, leading to inhibition of tumor growth in vitro and
n vivo (Bian et al., 2013; White et al., 2005).
The tumor cell response to P2X7R activation might depend
n the concentration of extracellular ATP and the P2X7R isoform
xpressed by the tumor cells. It was shown that there are two  P2X7R
soforms that respond in different ways. One is the full-length
2X7R, called P2X7A, which high extracellular ATP levels triggers
ustained pore activity and consequently induces cell death. The
econd isoform is a naturally occurring truncated isoform, called
2X7B, that does not have the carboxyl-terminal tail, thus lacking
ytotoxic activity even with high ATP concentrations because they
ail to cause pore formation (Adinolﬁ et al., 2010). We  have previ-
usly shown that ATP can increase radiotherapy-induced cell death
n vitro, depending on the P2X7R expression and functionality,
ince glioma cells that do not respond to ATP-P2X7R-cytotoxicity
resent a less functional and a lower expression of P2X7R, when
ompared to ATP-P2X7 sensitive glioma cells (Gehring et al.,
2012).
In this study, we demonstrate the importance of ATP-P2X7R in
he radiotherapy response in vitro, in vivo and ex vivo using humanchemistry & Cell Biology 68 (2015) 92–100 93
tumor samples. Our data show that P2X7R could be a useful tool
for evaluation of patients’ response to radiotherapy.
2. Material and methods
2.1. Cell culture and treatments
The human M059J glioma cells line was  purchased from Amer-
ican Type Culture Collection (ATCC – Rockville, MD,  USA) and the
mouse GL261 glioma cells line was  obtained from National Cancer
Institute (NCI – Frederick, MD,  USA). The M059J and GL261 cell lines
are considered radiosensitive as described previously (Daido et al.,
2005; Hoppe et al., 2000; Szatmari et al., 2006; Virsik-Kopp et al.,
2003). Cells were cultured in DMEM supplemented with 10% of fetal
bovine serum (FBS) at a temperature of 37 ◦C, a minimum relative
humidity of 95%, and an atmosphere of 5% CO2 in air. The cells were
treated for 24 h with ATP (5 mM).  Glioma cells were gamma irra-
diated at a 2 Gy-dose, using Cobalt Theratron Phoenix equipment
(Theratronics Ltd, Ontario, Canada), at a source-to-target distance
of 70 cm (Hoppe et al., 2000). Selective P2X7R antagonist A740003
(10 M)  (Riteau et al., 2010; Ulmann et al., 2010) was incubated
20 min  before treatment with ATP (5 mM).
2.2. Stable RNA interference
Human P2X7R (GeneID: 18439) was silenced by transduc-
tion of cells with lentivirus produced with the plasmid clone
ID NM 002562.4-801s1c1 from the Mission RNAi library from
Sigma–Aldrich. Mouse P2X7R (GeneID: 18439) (Rassendren et al.,
1997; Surprenant et al., 1996) was silenced by transduction of cells
with lentivirus produced with the plasmid clone ID NM 011027.1-
1368s1c1 from the Mission RNAi library from Sigma–Aldrich.
Non-target (SHC001) sequence was  used as a control. Lentiviruses
were produced by co-transfecting the Mission RNAi plasmid
with the helper plasmids pRSVREV, pVSV-G and pMDLgRRE in
sub-conﬂuent Hek293T cells with Superfect Reagent (Qiagen),
according to the manufacturer’s protocol. Three days after transfec-
tion, supernatants were collected twice every day during 1 week,
ﬁltered through a 0.22 mm membrane, and used immediately or
stored at −80 ◦C. Virus containing medium was added to human
and mouse target cells, at sub-conﬂuent stage in 24-well plates,
together with 4 g/ml of polybrene overnight. Cells were allowed
48 h to express the selection marker and were then selected with
puromycin 5.5 M for mouse and 1.8 M for human cell lines at
least 10 days. P2X7R silencing was conﬁrmed by western blot using
1:500 Alomone antibody against P2X7R (Alamone Cat APR004)
and 1:2000 Cell Signaling secondary antibody as described before
(Tamajusuku et al., 2010). The integrated optical density of western
blot bands were quantiﬁed using the ImageJ software.
2.3. Cell viability
For measuring cell viability, we performed MTT  assay and cell
counting. The cells were seeded at 5 × 103 cells per well in 96-well
plates for MTT  assay or 20 × 103 cells per well in 24-well plates
for cell counting and grown for 24 h. Subsequently, the cells were
for 24 h. For MTT  assay, 100 l of MTT  solution (90% DMEM/10%
MTT  5 mg/ml  in PBS) were added to the cells and incubated for
3 h. The formazan crystals, formed by tretrazolium cleavage, were
dissolved with 100 l of dimethyl sulfoxide (DMSO) for 10 min  and
quantiﬁed in a Spectra Max  M2e  (Molecular Devices) apparatus at
595 nm.  For cell counting, the medium was collected and 200 l of
trypsin/EDTA solution was  added to detach the cells, which were
counted on hemocytometer. The cell number of the control group
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not treated cells) was considered as 100%. The experiments were
arried out three times in triplicate.
.4. Ethidium bromide (EtBr) uptake assay
Glioma cells were seeded at 8 × 103 cells per well in 96-well
lates and grown for 24 h. After, the cells were incubated with
0 M ethidium bromide in the presence or absence of ATP
5 mM)  or BzATP (100 M)  for 3 min  and rinsed twice with PBS.
n some wells, cells were pre-incubated with the P2X7R selec-
ive antagonist A740003 (10 M)  for 15–20 min. To determine
hen the P2X7R receptor activation occurs after irradiation, cells
ere irradiated (2 Gy) and after 1, 3 and 24 h cells were incu-
ated only with 10 M ethidium bromide for 3 min  and rinsed.
he dye uptake was determined by ﬂuorescence microscopy using
n Olympus IX71 microscope. EtBr uptake was quantiﬁed by
mage J software (NIH) (http://www.uhnresearch.ca/facilities/wcif/
magej/). Corrected total cell ﬂuorescence was determined as
escribed in http://sciencetechblog.com/2011/05/24/measuring-
ell-ﬂuorescence-using-imagej/.
.5. Annexin V/PI ﬂow cytometry staining technique
Human M059J mock and M059J P2X7R silenced glioma cells
ere seeded at 8 × 104 cells per well in 12-well plates and treated
n the second day for 24 h as described previously. After this period,
ead cells were quantiﬁed by annexin V-FITC–propidium iodide
PI) double staining, using Annexin V-FITC Apoptosis Detection Kit
 (BD Biosciences) 24 h after treatment, according to the manufac-
urer’s instructions. Experiments were performed on FACS Canto
I Flow Cytometer (BD Biosciences), and the results were analyzed
sing FlowJo Software (Tree Star). The results are representative of
wo independent experiments.
.6. In vivo glioma model
In vivo GL261 mouse glioma model was previously validated
n our laboratory at PUCRS, Brazil. GL261 WT,  mock and P2X7R
ilenced glioma cells were cultured to approximately 70% con-
uence and resuspended at 3 × 105 cells/2 l DMEM.  The cells
ere injected using a 10-l Hamilton microsyringe coupled to an
nfusion pump (1 l/min × 2 min) at a depth of 3.0 mm into the
ight striatum (coordinates with regard to bregma: 2.0 mm lat-
ral) of adult male mouse C57/BL6 (nearly 8 weeks old, 25–30 g)
reviously anesthetized by an intraperitoneal (i.p.) administra-
ion of ketamine/xylazine. After 20 days, mice were euthanized
nd the entire brain was removed, sectioned and ﬁxed with 10%
araformaldehyde. Consecutive 4-m-thick longitudinal sections
ere stained with hematoxylin-eosin (H&E). All the procedures
ere approved by the PUCRS’ Animal Ethics Committee under pro-
ocol number 09/00123.
.7. Radiotherapy protocol
Gamma  irradiation procedure was adapted from Newcomb et al.
2010) and Vinchon-Petit et al. (2010), for mice (Newcomb et al.,
010; Vinchon-Petit et al., 2010). Brieﬂy, mice were irradiated
nder mild anesthesia by i.p. administration of ketamine/xylazine
0 and 80 mg/kg, respectively; to ensure immobilization to allow
adiation to be delivered directly to the tumor-bearing hemisphere.
adiation was delivered on days 11 and 15 after implantation to the
ead of four mice each time that were placed in a prone position
s described by Vinchon-Petit et al., 2010. The total radiation dose
dministered was  8 Gy given on 2 days – doses of 4 Gy each (Fig. 4A).
adiation was delivered using Cobalt Theratron Phoenix equipmentochemistry & Cell Biology 68 (2015) 92–100
(Theratronics Ltd, Ontario, Canada) at Hospital São Lucas, PUCRS,
Porto Alegre, Brazil.
2.8. Pathological analysis and tumor volume quantiﬁcation
For this protocol, the results are representative of ﬁve animals
per group. At least three H&E sections of each tumor were ana-
lyzed by an experienced pathologist, blinded for the experimental
groups. For tumor size quantiﬁcation, images were captured using
a digital camera (G9, Canon) connected to the microscope (Stemi
DV4, Zeiss) and analyzed using AxioVision 4.7 image tool software.
The total volume (mm3) of the tumor was computed by sum-
ming the segmented areas and by the multiplication of the slice
resolution.
2.9. Human sample immunohistochemistry
Eighteen histological samples of human gliomas were collected
between January 2004 and June 2008 from patients who under-
went glioma surgical resection at the Pathology Department from
the University Hospital of the Federal University of Rio Grande
do Sul (HCPA-UFRGS; Porto Alegre, Brazil) and the diagnostic
was made by a pathologist. All patients signed an informed con-
sent allowing the use of part of the removed tissue for scientiﬁc
purposes. Samples were obtained in accordance with approved
ethical standards of the institutional research ethics commit-
tee (GPPG document number 08-259, HCPA-UFRGS). The biopsies
were processed as previously described (Braganhol et al., 2009).
Anti-P2X7 antibody (Santa Cruz Biotechnology) was used at the
dilution of 1:100 followed by anti-IGG peroxidase and diaminoben-
zidine staining. The samples were lightly counterstained with
H&E in order to conﬁrm the tumor localization. P2X7R expres-
sion was  quantiﬁed by WCFI Image J software (NIH) (http://www.
uhnresearch.ca/facilities/wcif/imagej/) as it follows: the immuno-
histochemistry sample images, captured at the same light intensity,
were submitted to color deconvolution with “Plugins/Color Func-
tions” and “H&E DAB”. The DAB image generated was  quantiﬁed
by using “Analyze/Measure” as previously described (Braganhol
et al., 2009). Patients were divided according to P2X7R expres-
sion above and below median expression and the survival of the
two independent groups was evaluated in a Kaplan–Meier survival
plot.
2.10. mRNA expression and correlation with patient’s survival
The results presented here are in whole or part based upon data
generated by REpository for Molecular BRAin Neoplasia DaTa (REM-
BRANDT), established by NCI and NIH (National Institute of Health).
Information about REMBRANDT and TCGA and the investigators
and institutions that constitute the REMBRANDT research network
can be found at https://caintegrator.nci.nih.gov/rembrandt/home.
do. The Kaplan–Meier survival plot for Gene Expression Data was
generated with the following entries: ‘P2RX7’, as gene symbol in
all the plots, ‘all gliomas’ as sample group. National Cancer Insti-
tute. 2005. REMBRANDT home page http://rembrandt.nci.nih.gov
(accessed 03.10.14).
2.11. Statistical analysisData were analyzed by test-t student or one-way analysis of
variance (one-way ANOVA), followed by Tukey–Kramer post hoc
test or, using GraphPad Software 5.0 (San Diego, CA, U.S.A.). p values
<0.05 were taken to indicate statistical signiﬁcance.
l of Bio
3
3
g
i
m
t
h
P
n
l
o
c
o
c
a
s
(
a
t
d
a
a
3
r
2
2
n
w
c
(
m
(
a
a
p
n
d
t
a
t
3
s
i
t
r
o
t
r
d
a
A
p
c
t
dM.P. Gehring et al. / The International Journa
. Results
.1. P2X7R functionality and silencing on M059J and GL261
lioma cells
The cell lines used in this work are sensitive to ATP-P2X7R-
nduced cell cytotoxicity. The ATP dose response curve for GL261
ouse glioma cell line is shown in Fig. 1A. In order to demonstrate
he participation of P2X7R in radiation-induced cell death, M059J
uman and GL261 mouse glioma cells were stably transduced with
2X7R RNAi vector (silenced) or with scramble-RNAi vector as a
egative control (mock cell line). Relative protein quantiﬁcation
evels of western blot bands showed a P2X7R silencing efﬁciency
f 60%, relative to mock cells protein levels (Fig. 1B).
To analyze the P2X7R pore functionality on GL261 and M059J
ells it was performed EtBr uptake assay (Fig. 1C and D). Both ATP
r BzATP treatments induced EtBr uptake on the WT  and mock
ells which was signiﬁcantly reduced either by the selective P2X7R
ntagonist A740003 (10 M)  or by the P2X7R RNAi vector (P2X7R
ilenced cells), as shown in the corrected total cell ﬂuorescence
Fig. 1E and F). Lastly, we observed that P2X7R silencing or P2X7R
ntagonist (A740003) were able to reduce the ATP-induced cyto-
oxicity on GL261 and M059J cells (Fig. 1G). Taking together, these
ata showed that GL261 and M059J cells present a functional P2X7R
nd the P2X7R silencing reduced ATP cytotoxicity and P2X7R pore
ctivity.
.2. Radiotherapy induces P2X7R activation and P2X7R silencing
educes radiotherapy-induced cell cytotoxicity in vitro
GL261 and M059J are both radiosensitive cell lines (Daido et al.,
005; Hoppe et al., 2000; Szatmari et al., 2006; Virsik-Kopp et al.,
003). Here, we show that gamma  radiation (2 Gy) reduced cell
umber to a similar extent as seen for ATP, in a P2X7R-dependent
ay, since both P2X7R antagonist and P2X7R silencing blocked the
ell cytotoxicity caused by gamma-radiation treatment after 24 h
Fig. 2A).
To analyze when P2X7R is activated after radiotherapy we
easured the EtBr uptake 1, 3 and 24 h after radiotherapy (2 Gy)
Fig. 2B). Our data showed that P2X7R activation is time-dependent,
s the highest EtBr uptake was observed 24 h after radiotherapy
nd both P2X7R antagonist treated cells and P2X7R silenced cells
resented less EtBr uptake, indicating a P2X7R-dependent mecha-
ism. One-hour after irradiation, EtBr uptake was not signiﬁcantly
ifferent from the untreated cells, i.e. plate transported to the radio-
herapy facility, but not irradiated (data not shown). However, 3-h
fter radiotherapy, EtBr was found incorporated when compared
o control cells.
.3. Radiotherapy-induced cell death is less efﬁcient on P2X7R
ilenced glioma cell
The treatment with ATP (5 mM)  or radiotherapy (2 Gy) alone
nduced annexin V incorporation rates of 75% and 72.1%, respec-
ively, in M059J human glioma cells after 24 h. The combination of
adiotherapy with ATP incubation induced a signiﬁcant increase
f annexin V incorporation (96.6%), when compared to these
reatments alone, showing that ATP acts synergistically with
adiotherapy. Additionally, when the cells were treated before irra-
iation with P2X7R antagonist A740003, it was possible to observe
 decrease in annexin V incorporation (20.0%) and even with an
TP stimulus (5 mM)  after A740003 + irradiation annexin V incor-
oration was still signiﬁcantly reduced when compared to the
o-treatment ATP and irradiation (25.9%) (Fig. 3A–C). Furthermore,
he M059J P2X7R silenced cells also presented resistance to cell
eath induced by ATP, radiotherapy or both treatments togetherchemistry & Cell Biology 68 (2015) 92–100 95
(Fig. 3B and C) – 11.5%, 12.3% and 16.2% of annexin V incorporation,
respectively; suggesting that ATP-P2X7R is an important pathway
to the radiotherapy response.
3.4. P2X7R expression is important for radiotherapy success
in vivo
GL261 WT-bearing mice treated with radiotherapy 8 Gy (4 Gy
on days 11 and 15 after implantation, Fig. 4A) showed a signif-
icant reduction in tumor volume when compared to untreated
mice, in agreement with published data using the same model
(Szatmari et al., 2006). Interestingly, GL261 P2X7R silenced-bearing
mice developed tumors with similar size as WT,  but these tumors
were completely resistant to radiotherapy, showing that a P2X7R
is essential for radiotherapy response in an in vivo glioma model
(Fig. 4B and C).
3.5. High P2X7R expression is a good prognostic factor for glioma
radiosensitivity and survival probability in human
Human glioma biopsies were analyzed regarding P2X7R expres-
sion by immunohistochemistry, and patients were separated into
two groups: with high and low P2X7R expression. Patients whose
glioma biopsies presented high P2X7R staining presented longer
survival when compared to patients with low P2X7R expression
(Fig. 5A). The median survival time (MST) of patients with low
P2X7R was  14 months, whereas patients with high P2X7R expres-
sion have a MST  higher than 80 months. This correlation was
conﬁrmed by mRNA expression data obtained by microarray anal-
ysis from the Rembrandt database. The analysis of data from 343
patients with gliomas classiﬁed in different grades also found that
patients whose glioma presented an upregulation of P2X7R mRNA
expression have signiﬁcantly higher MSTs, when compared to those
whose tumors expressing P2X7R in the intermediary and lower
level (Fig. 5B). More interesting, our samples are also analogous
with Rembrandt data comparing GBM occurrence. Within the low
P2X7R expression group, 78% of the biopsies were GBM against
44% of this kind of tumor in high P2RX7-expressing samples. Data
from Rembrandt platform also demonstrated that the majority
(68%) of gliomas with down-regulated P2X7R expression was GBM,
whereas in the up-regulated P2X7R expression group, GBM  were
just 21%, suggesting that P2X7R might be one of the genes sup-
pressed during glioma malignant transformation.
We  also used data from Rembrandt platform to analyze the
P2X7R expression and ‘all glioma’ patients that were describe
on the platform as underwent ‘radiotherapy’ (all types) prior or
after surgery. As shown in Fig. 5C, the analysis of data from 47
patients with different gliomas showed that patients presenting
higher P2X7R expression levels seem to respond better to radio-
therapy with a higher MSTs, when compared to patients whose
glioma present low P2X7R expression levels. Conceivably, with a
larger number of samples it is possible to clearly show the cor-
relation between radiotherapy response and P2X7R expression
level.
4. Discussion
The classical glioma treatment is surgery to provide maxi-
mal  tumor resection. However, total tumor resection is almost
impossible due to the inﬁltrative nature of gliomas. Therefore,
surgery is followed by radiotherapy, which clearly improves sur-
vival rates (Bassi et al., 2008). Its known that many different genes
displayed signiﬁcantly altered gene expression following radio-
therapy (Lindgren et al., 2012). In recent years, there was  an
increase in the understanding of the molecular and genetic basis
by identifying genes and pathways that are involved in tumor
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Fig. 1. P2X7R functionality and silencing on M059J and GL261 glioma cells. (A) Effect of ATP (1, 3, and 5 mM)  and BzATP (100 M)  on cell viability of GL261 cell line after 24 h.
(B)  Quantiﬁcation of western blots using scanning and ImageJ software (n ≥ 4). Results are expressed as relative density of the bands. Mock cell line were used as control.
LC:  loading control. Each column represents the mean ± SEM, *p < 0.01. (C) GL261 and (D) M059J cells ethidium bromide uptake after stimulation with ATP (5 mM)  or BzATP
(100  M).  Control, treated only with ethidium bromide. (E) GL261 and (F) M059J corrected total cell ﬂuorescence (CTCF) of ethidium bromide uptake calculated using Image
J,  as described in Methods. (G) Effect of ATP (5 mM)  and selective P2X7R antagonist A740003 (10 M) treatment on cell viability of GL261 and M059J cells after 24 h. All
experiments were carried out at least three times. WT cells (white bars), mock cells (gray bars) and P2X7R silenced cells (black bars). Each column represents the mean ± SEM.
*Comparison to the respective control and #comparison between groups. * or #p < 0.05; ** or ##p < 0.01 and *** or ###p < 0.001, as determined by ANOVA with Tukey’s post
hoc  test.
Fig. 2. Radiotherapy-induced cell death is impaired in the absence of P2X7R. (A) Effect of treatment with ATP (5 mM)  or irradiation (2 Gy) on cell viability of M059J and GL261
glioma  lines after 24 h. (B) Corrected total cell ﬂuorescence (CTCF) of ethidium bromide uptake 3 and 24 h after irradiation (2 Gy) on GL261 and M059J cells, calculated using
Image J, as described in Methods. The P2X7R antagonist A740003 (10 M)  was  added 15–20 min  prior irradiation. Mock cells (gray bars) and P2X7R silenced cells (P2X7R−/−)
(black  bars). *Comparison to the respective control and #comparison between groups. Each column represents the mean ± SEM. * or #p < 0.05; ** or ##p < 0.01 and *** or
###p  < 0.001, as determined by ANOVA with Tukey’s post hoc test.
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Fig. 3. Radiotherapy and ATP-P2X7R induce apoptosis and is less efﬁcient on P2X7R silenced cells. Flow cytometry dot plot of Annexin V/PI positive cells 24 h after treatment
with  ATP (5 mM),  radiotherapy (2 Gy) and/or pre-treatment with A740003 (10 M) on (A) M059J mock cells, (B) M059J P2X7R silenced cells. (C) Percentage of Annexin
V  positive cells. Each sample has 50,000 cells. Data shown is representative of at least two  independent experiments. Mock cells (gray bars), Mock cells treated prior
with  A740003 (dotted gray) and P2X7R silenced cells (black bars). *Comparison to the respective control and #comparison between groups. Each column represents the
mean  ± SEM. ##p < 0.01 and *** or ###p < 0.001, as determined by ANOVA with Tukey’s post hoc test.
Fig. 4. P2X7R levels and sensitivity to radiotherapy-induced glioma cell death in vivo. (A) GL261 WT,  mock and P2X7R silenced glioma cells were cultured to approximately
70%  conﬂuence and 3 × 105 cells/2 l DMEM were injected into the right striatum of adult mouse C57/BL6. Mice were treated with radiotherapy on days 11 and 15 after
implantation 4 Gy each day. The total radiation dose administered was 8 Gy. After 20 days, mice were decapitated and the entire brain was removed to further analysis. (B)
R ain tre
q er gro
b
r
a
t
sepresentative sections of GL261 WT and P2X7R silenced cells implanted on mice br
uantiﬁcation of implanted gliomas. Data represent the mean ± SD of ﬁve animals p
y  ANOVA with Tukey’s post hoc test.adiosensitivity. DNA variants can contribute to radioresistance
nd the identiﬁcation of these genes can be a targeted to increase
he tumors sensitivity to radiation (Smirnov et al., 2012). We  have
hown that the P2X7R is a radiation-responsive gene since P2X7Rated with radiotherapy (RT) or not treated (control) stained with HE. (C) Tumor size
up. Each column represents the mean ± SEM *** or ###p < 0.001 #, as determinedexpression and activity is signiﬁcantly increased after irradiation
in some glioma tumor cells (Gehring et al., 2012). Furthermore, it
is already known that ATP is released from cancer cells exposed
to radiation (Ohshima et al., 2010), leading to the hypothesis that
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Fig. 5. High P2X7R expression in glioma positively correlates with survival probability. (A) Survival curve of 18 human glioma samples considering P2X7R protein expression
a  immu
B  from R
( se, con
P
d
t
dbove  (high) and below (low) the median expression level. Representative pictures of
ars  represent 100 m.  (B) Kaplan–Meier survival plot of 343 patients with gliomas
C)  Kaplan–Meier survival plot of 47 patients with gliomas from Rembrandt databa2X7R is activated after radiotherapy, consequently inducing cell
eath in the manner of apoptosis. It is important to note that the
umor cells need to present a functional P2X7R to induced cell
eath, as we already showed that tumor cells that not respond tonohistochemistry of P2X7R in gliomas with high and low P2X7R protein expression.
embrandt database, considering P2X7R mRNA expression analyzed by microarray.
sidering P2X7R mRNA expression only of patients that underwent radiotherapy.ATP cytotoxicity present a minor expression and functional P2X7R
(Gehring et al., 2012). We  believe that P2X7R radiation-responsive
gene is one of the many pathways that irradiation modulate and
use to induce cell death.
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We  have shown by EtBr uptake that GL261 and M059J cell lines
resent a functional P2X7R and that these cells are ATP sensitive.
ither P2X7R silencing or P2X7R antagonist (A740003) were able to
lock the ATP-P2X7R-induced pore opening and cytotoxicity. Inter-
stingly, M059J and GL261 cells treated with P2X7R antagonist,
r P2X7R silenced cell lines failed to respond to radiotherapy-
nduced cell death in vitro, showing that there is a correlation with
unctional P2X7R and radiotherapy-induced cell death. P2X7R acti-
ation seems to occur at least 2 h after radiotherapy, as we  observed
n increase in EtBr uptake after 3 h, but not after 1 h of irradiation
hen compared to untreated cells, P2X7R antagonist (A740003)
reated cells or P2X7R silenced cells. This result showed that the
ctivation of P2X7R is time-dependent, as EtBr uptake signiﬁcantly
ncreases after 24 h of irradiation. These data corroborate with the
dea that P2X7R pore activity is activated by high ATP concentration
r, in this case, when exposure for a long period to ATP (White and
urnstock, 2006), that is released from cells undergoing immuno-
enic cell death (ICD) (Galluzzi et al., 2013; Kroemer et al., 2013).
We observed that either ATP or radiotherapy induced apoptosis
ell death (characterized by an increased in annexin V incorpo-
ation) after 24 h. This data is in agreement with previous data
escribing that irradiation induces apoptotic cell death in glioma
ells (Ma  et al., 2013a) and ATP-P2X7R activation mediates apopto-
is in different types of cancer (Fang et al., 2013). The intervention
ith P2X7R antagonist (A740003) or P2X7R silencing compromised
he induction of apoptosis by ATP and radiotherapy, showing that
here is a link between P2X7R activation and radiotherapy-induced
ell death. This P2X7R relevance to radiotherapy response in glioma
ells was also veriﬁed in vivo. Corroborating with the in vitro stud-
es, our results showed that GL261 P2X7R silenced-bearing mice
ailed to respond to radiotherapy (8 Gy total). Otherwise, GL261
T-bearing mice, that constitutively express a functional P2X7R,
resented a satisfactory outcome following radiotherapy. In the
umor micro-environmental, the ATP released after radiotherapy
Ohshima et al., 2010) by ICD in response to radiotherapy (Galluzzi
t al., 2013; Kroemer et al., 2013) activate P2X7R on dendritic
ells, thereby triggering IL-1 release, which in turn enhances Ag
resentation to CD4+ T lymphocytes, and ﬁnally enhances antitu-
or  immunity (Di Virgilio, 2012), resulting in a synergistic action
f ATP-P2X7R and radiotherapy and an enriched radiotherapy-
nduced immune response.
Interpretation of our data showing an anti-tumoral effect of
2X7R is made more complex by the observation that tonic, as
pposed to acute pharmacologic stimulation, may  have a trophic,
rowth-promoting, rather than cytotoxic effect. This suggests that
pon ATP stimulation of P2X7 on tumor cells can result in differ-
nt outcomes: (i) as a reaction to this death-related signal, they can
ownregulate P2X7 to avoid apoptosis or (ii) as a cancer-promoting
ignal to survive and enhance invasion of new niches (Roger and
elegrin, 2011). Some studies showed that tumor cells expressing
2X7R also expressed elevated amounts of VEGF and more devel-
ped vascular network (Adinolﬁ et al., 2012), increased cell invasion
nd migration, possibly via PI3K/AKT and ERK1/2 pathway, modu-
ation of E-cadherin, MMP-13, SK3 channels- and cystein cathepsin
Jelassi et al., 2011; Qiu et al., 2014; Xia et al., 2015). However, other
tudies show that functional P2X7R activation induces apoptosis
n melanoma, squamous cell skin cancer, lung cancer, glioma cells
nd cervical cancer (Tamajusuku et al., 2010; Wang et al., 2004;
hite et al., 2005), possibly through rapid cytotoxic effects caused
y ATP exposure on tumor cells that affects cell growth/survival
n vitro and in vivo (Bian et al., 2013). Another study concluded
hat tumor cell P2X7-dependent apoptosis is mediated by calcium
nﬂux via P2X7R pores, and involves the caspase-9 (mitochondrial)
athway (Fu et al., 2009; Wang et al., 2004) and the diminished
ro-apoptotic effect of BzATP in cancer cells is possibly the result
f low expression of the P2X7R (Fu et al., 2009). Moreover, breastchemistry & Cell Biology 68 (2015) 92–100 99
cancer patients harboring a P2X7R gene with decreased activity
have a signiﬁcantly greater risk of progression to metastatic dis-
ease (Ghiringhelli et al., 2009). Interestingly, we also investigated
the involvement of P2X7R in the glioma pathobiology using human
glioma biopsies and our result is in accordance with the former
result mentioned. Biopsies presenting increased P2X7R expression
had less GBM tumors diagnosis, with a higher median survival.
A survey of Rembrandt database revealed a similar result a posi-
tive correlation between P2X7R expression in gliomas and survival
of patients. This correlation was  found both at the protein level
and at mRNA level. The similarity of these results with other brain
tumors information points to an important inﬂuence of P2X7R on
tumor progression and probability of survival. A recently study also
showed a signiﬁcant difference in the progression-free survival and
overall survival in the non-small cell lung cancer patients with high
P2X7 expression when compared with that of patients with low
expression (Boldrini et al., 2015). Moreover, using Rembrandt data,
even though without an expressive number of patients, we showed
that patients with a higher P2X7R expression tend to respond better
to radiotherapy treatment, at least in the ﬁrst two months, showing
that patients that dissatisfy in respond to radiotherapy express less
P2RX7.
Thus, we  consider that P2X7R is one of the radiation-responsive
genes as part of many pathways that can be activated by irradiation
to induce cell death, and that this receptor can be used to predict
glioma radiosensitivity.
5. Conclusion
These data show the signiﬁcance of a high and functional P2X7R
expression on glioma cells to a successful radiotherapy response.
Furthermore, our study sheds light on this gene as a predictor of the
sensitivity of cancer patients to radiotherapy and median survival.
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